#China #Shanghai #IPO #Qiming Venture Partners #LongBio Pharma

LongBio Pharma's Historic Listing on the Hong Kong Stock Exchange

On June 5, 2026, LongBio Pharma, an innovative drug developer focused on allergic and autoimmune diseases, made its debut on the Hong Kong Stock Exchange. This significant milestone marks the seventh initial public offering (IPO) of Qiming Venture Partners for the year, highlighting the growing interest and investment in the biopharmaceutical sector.

LongBio Pharma, which operates under the stock symbol 01779.HK, raised considerable attention by issuing its shares at a price of HK$96.06. Following an enthusiastic response from investors, shares opened at HK$144.30, leading to a market capitalization of HK$10.7 billion. This positive reception speaks volumes about the trust and confidence investors place in the company’s capabilities and future prospects.

About LongBio Pharma

Founded in 2020, LongBio Pharma was established to focus on the in-house discovery and development of biopharmaceutical products that target allergic and autoimmune diseases. The founding team comprises experienced professionals who have successfully navigated the complexities of drug discovery, clinical development, and regulatory registration, making LongBio Pharma a formidable player in the industry.

Dr. Sun Naichao, one of the co-founders, is notably recognized as the original inventor of omalizumab, a groundbreaking anti-IgE antibody that has significantly improved the treatment of allergic conditions. His deep commitment and extensive expertise in this field position LongBio Pharma on a path to innovation and excellence.

Meanwhile, Dr. Liu Heng, co-founder and CEO of LongBio Pharma, brings over 15 years of experience in biopharmaceutical research and development, playing a crucial role in establishing the company’s projects both domestically and internationally.

Product Pipeline and Innovations

LongBio boasts a robust pipeline of products that cater to various therapeutic areas, including rhinology, dermatology, respiratory conditions, hematology, and nephrology. The company’s flagship product, LP-003, is a novel anti-IgE antibody designed to inhibit IgE-mediated allergic reactions. Early results show that LP-003 has outperformed omalizumab in treating chronic spontaneous urticaria (CSU), indicating its potential for becoming a key player in the market.

Additionally, LP-005, another flagship product, is a unique bi-functional complement antibody-fusion protein that targets C5 and C3b, showcasing promising therapeutic advantages over single-target complement inhibitors. This innovative formulation positions LongBio's products ahead of the curve in addressing various health conditions.

Strategic Investment and Market Implications

Qiming Venture Partners, the principal institutional investor in LongBio Pharma, has actively supported the company’s growth, having invested as the lead in its B2 round of financing in 2024 and co-leading the subsequent C round in 2025. Prior to the IPO, Qiming held a 4.27 percent stake in the company, reflecting its strong belief in LongBio's potential.

Dr. Kan Chen, a partner at Qiming, commented on the IPO as a pivotal moment for LongBio Pharma, emphasizing its transition from laboratory research to market-ready solutions. The rising prevalence of allergic diseases in China, such as allergic rhinitis and asthma, underscores the demand for effective treatments, further enhancing LongBio's commercial viability.

Conclusion

LongBio Pharma's listing is not only a significant achievement for the company but also a clear signal of investor confidence in the future of biopharmaceuticals within the Chinese market. The innovative approach to drug development, backed by a seasoned team and strategic investments, paves the way for LongBio Pharma to emerge as a leader in addressing unmet medical needs in the realm of allergic and autoimmune conditions. As they advance, all eyes will be on how LongBio Pharma continues to innovate and grow in this competitive industry.